Posttranscriptional control of gene expression

基因表达的转录后控制

基本信息

项目摘要

Summary Our research focuses on the regulation of gene expression, in particular the mechanisms controlling cellular and viral mRNA expression. A critical step in the mRNA metabolism is the transport of the mRNA from the nucleus to the cytoplasm. Analysis of retroviral systems, pioneered by research on HIV-1, have shed light into some important aspects of nuclear mRNA export and have provided critical insights into mechanisms governing cellular mRNA and protein transport. We are utilizing retroviral systems to identify and study mechanisms of mRNA metabolism using a combination of biochemistry, functional genomics, and proteomics. The dissection of the mechanisms of posttranscriptional control and nucleocytoplasmic trafficking of macromolecules are relevant to understand processes involved in cellular gene expression as well as virus expression. We identified the mRNA export requirement of the simian type D retroviral transcript which is mediated by the cis acting RNA export element (CTE) and its binding partner, the cellular protein NXF1. We further found that the cellular NXF1 protein acts as the key nuclear receptor for cellular mRNAs, and that this function is conserved in metazoa. We identified that the mobility of the murine LTR-retroelements (Intracisternal A particle retroelements) depends on the presence of the cis-acting RNA transport element RTE. The export and expression of the retroelement transcript depends on RTE. Thus, RTE acts like the CTE and is a potent signal for a cellular RNA export factor. This finding reveals that, despite a complex evolutionary history, retroelements and retroviruses share the dependency on posttranscriptional regulation. We identified the RNA binding motif 15 (RBM15) protein as the cellular factor that binds and exports RTE-containing mRNAs. RBM15, a novel mRNA export factor, belongs to the SPEN family of proteins and is conserved among metazoa. Importantly, we found that RBM15 acts as molecular link and tethers the RTE-mRNAs to the NXF1 export pathway. Thus, these experiments have identified another important factor of the mRNA export route. Since HIV gag and env mRNAs are poorly expressed in the absence of potent posttranscriptional Rev-RRE regulation, these mRNAs serve as excellent reporters to study improvement of mRNA expression at the posttranscriptional level. We demonstrated that the combination of RNA export elements CTE and RTE synergistically improves gag and env expression. Thus, this discovery provided us with a simple novel technology to improve gene expression for DNA mediated gene transfer applications. We also studied an example of regulated cellular mRNA expression, namely the expression of cytokine genes, in particular interleukin 15 (IL-15). IL-15 is a multifunctional cytokine expressed in many tissues. Its use as molecular adjuvant in vaccine and in cancer immunotherapy is promising. In addition to regulation at the transcriptional level, IL-15 expression is controlled at several posttranscriptional and posttranslational steps such as mRNA stability, translation, intracellular trafficking and secretion. As a direct extension of our research of retroviral mRNAs, we studied expression of IL-15. Expression from the native mRNA is poor and upon RNA-optimization we found great improvement for murine, rhesus macaque and human IL-15. Thus, the methodology utilized to optimize HIV gene expression also let to improved IL-15 expression from simple DNA vectors. The combination of posttranscriptional and posttranslational modification led to the generation of efficient expression plasmids producing several hundred fold higher levels of bioactive IL-15. Such expression plasmids are part of our cocktail of DNA plasmids used in preventive and immunotherapeutic vaccination protocols in SIV. These optimized expression vectors have potential applications in vaccine and immunotherapy approaches against AIDS and cancer.
我们的研究重点是基因表达的调控,特别是控制细胞和病毒mRNA表达的机制。mRNA代谢的一个关键步骤是mRNA从细胞核转运到细胞质。由HIV-1研究开创的对逆转录病毒系统的分析,揭示了细胞核mRNA输出的一些重要方面,并为控制细胞mRNA和蛋白质运输的机制提供了关键的见解。我们正在利用逆转录病毒系统,结合生物化学、功能基因组学和蛋白质组学来识别和研究mRNA代谢机制。对转录后调控和大分子核胞质转运机制的剖析,对于理解细胞基因表达和病毒表达过程具有重要意义。我们确定了由顺式作用RNA输出元件(CTE)及其结合伙伴细胞蛋白NXF1介导的猿猴D型逆转录病毒转录物的mRNA输出需求。我们进一步发现细胞NXF1蛋白作为细胞mrna的关键核受体,并且这种功能在后生动物中是保守的。我们发现小鼠体内A颗粒逆转录因子(LTR-retroelements)的迁移取决于顺式作用RNA转运因子RTE的存在。逆转录因子的输出和表达依赖于RTE。因此,RTE的作用类似于CTE,是细胞RNA输出因子的有效信号。这一发现表明,尽管具有复杂的进化史,逆转录因子和逆转录病毒都依赖于转录后调控。我们发现RNA结合基序15 (RBM15)蛋白是结合和输出含有rte的mrna的细胞因子。RBM15是一种新的mRNA输出因子,属于SPEN蛋白家族,在后生动物中保守。重要的是,我们发现RBM15作为分子连接并将rte - mrna连接到NXF1输出途径。因此,这些实验已经确定了mRNA输出途径的另一个重要因素。由于HIV gag和env mRNA在缺乏有效的转录后Rev-RRE调控的情况下表达不良,因此这些mRNA可以作为研究转录后水平mRNA表达改善的优秀报告者。我们证明了RNA输出元件CTE和RTE的组合可以协同提高gag和env的表达。因此,这一发现为我们提供了一种简单的新技术来改善DNA介导的基因转移应用中的基因表达。我们还研究了一个受调控的细胞mRNA表达的例子,即细胞因子基因的表达,特别是白细胞介素15 (IL-15)。IL-15是一种在多种组织中表达的多功能细胞因子。它在疫苗和癌症免疫治疗中作为分子佐剂的应用前景广阔。除了转录水平的调控外,IL-15的表达还受到转录后和翻译后几个步骤的控制,如mRNA的稳定性、翻译、细胞内运输和分泌。作为逆转录病毒mrna研究的直接延伸,我们研究了IL-15的表达。原生mRNA的表达较差,经过rna优化,我们发现小鼠、恒河猴和人IL-15的表达有很大改善。因此,优化HIV基因表达的方法也可以提高简单DNA载体上IL-15的表达。转录后和翻译后修饰的结合导致高效表达质粒的产生,其生物活性IL-15的水平提高了数百倍。这种表达质粒是我们用于SIV预防和免疫治疗性疫苗接种方案的DNA质粒混合物的一部分。这些优化的表达载体在艾滋病和癌症的疫苗和免疫治疗方法中具有潜在的应用前景。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
RTE and CTE mRNA export elements synergistically increase expression of unstable, Rev-dependent HIV and SIV mRNAs.
RTE 和 CTE mRNA 输出元件协同增加不稳定、Rev 依赖性 HIV 和 SIV mRNA 的表达。
  • DOI:
    10.1186/1742-4690-3-6
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    3.3
  • 作者:
    Smulevitch,Sergey;Bear,Jenifer;Alicea,Candido;Rosati,Margherita;Jalah,Rashmi;Zolotukhin,AndreiS;vonGegerfelt,Agneta;Michalowski,Daniel;Moroni,Christoph;Pavlakis,GeorgeN;Felber,BarbaraK
  • 通讯作者:
    Felber,BarbaraK
Structural and functional analysis of the RNA transport element, a member of an extensive family present in the mouse genome.
RNA 转运元件(小鼠基因组中存在的一个广泛家族的成员)的结构和功能分析。
  • DOI:
    10.1128/jvi.79.4.2356-2365.2005
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Smulevitch,Sergey;Michalowski,Daniel;Zolotukhin,AndreiS;Schneider,Ralf;Bear,Jenifer;Roth,Patricia;Pavlakis,GeorgeN;Felber,BarbaraK
  • 通讯作者:
    Felber,BarbaraK
The mRNA export in Caenorhabditis elegans is mediated by Ce-NXF-1, an ortholog of human TAP/NXF and Saccharomyces cerevisiae Mex67p.
秀丽隐杆线虫中的 mRNA 输出由 Ce-NXF-1 介导,Ce-NXF-1 是人 TAP/NXF 和酿酒酵母 Mex67p 的直系同源物。
  • DOI:
    10.1017/s1355838200000832
  • 发表时间:
    2000
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Tan,W;Zolotukhin,AS;Bear,J;Patenaude,DJ;Felber,BK
  • 通讯作者:
    Felber,BK
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BARBARA K FELBER其他文献

BARBARA K FELBER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BARBARA K FELBER', 18)}}的其他基金

PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
SIVMAC239 变异体在新生猕猴中的致病性
  • 批准号:
    7958994
  • 财政年份:
    2009
  • 资助金额:
    $ 103.6万
  • 项目类别:
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
SIVMAC239 变异体在新生猕猴中的致病性
  • 批准号:
    7715569
  • 财政年份:
    2008
  • 资助金额:
    $ 103.6万
  • 项目类别:
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
SIVMAC239 变异体在新生猕猴中的致病性
  • 批准号:
    7562160
  • 财政年份:
    2007
  • 资助金额:
    $ 103.6万
  • 项目类别:
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
SIVMAC239 变异体在新生猕猴中的致病性
  • 批准号:
    7349647
  • 财政年份:
    2006
  • 资助金额:
    $ 103.6万
  • 项目类别:
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
SIVMAC239 变异体在新生猕猴中的致病性
  • 批准号:
    7165446
  • 财政年份:
    2005
  • 资助金额:
    $ 103.6万
  • 项目类别:
PATHOGENICITY OF SIVMAC239 VARIANTS IN NEONATAL MACAQUES
SIVMAC239 变异体在新生猕猴中的致病性
  • 批准号:
    6971437
  • 财政年份:
    2004
  • 资助金额:
    $ 103.6万
  • 项目类别:
PATHOGENICITY OF REV INDEPENDENT SIVMAC239 VARIANTS IN NEONATAL MACAQUES
REV 独立 SIVMAC239 变异体在新生猕猴中的致病性
  • 批准号:
    6940445
  • 财政年份:
    2003
  • 资助金额:
    $ 103.6万
  • 项目类别:
Pathogenicity and immunogenicity of live attenuated SIV
减毒活SIV的致病性和免疫原性
  • 批准号:
    6559234
  • 财政年份:
  • 资助金额:
    $ 103.6万
  • 项目类别:
Prevention of AIDS
预防艾滋病
  • 批准号:
    7338497
  • 财政年份:
  • 资助金额:
    $ 103.6万
  • 项目类别:
Pathogenicity and immunogenicity of live attenuated SIV
减毒活SIV的致病性和免疫原性
  • 批准号:
    7052679
  • 财政年份:
  • 资助金额:
    $ 103.6万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 103.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 103.6万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 103.6万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 103.6万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 103.6万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 103.6万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 103.6万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 103.6万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 103.6万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 103.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了